{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/angio-oedema-anaphylaxis/management/angio-oedema-without-anaphylaxis/","result":{"pageContext":{"chapter":{"id":"654a5e70-49b7-58b4-b976-7e94c44b3074","slug":"angio-oedema-without-anaphylaxis","fullItemName":"Scenario: Angio-oedema without anaphylaxis","depth":2,"htmlHeader":"<!-- begin field cac34cbe-27d4-49f3-992f-2028a7f4ebe7 --><h2>Scenario: Angio-oedema without anaphylaxis</h2><!-- end field cac34cbe-27d4-49f3-992f-2028a7f4ebe7 -->","summary":"Covers the management and follow up of a person with angio-oedema without any airway symptoms or signs of circulatory collapse.","htmlStringContent":"<!-- begin item 995af068-65c3-4136-8ff8-8b919a0aec86 --><!-- begin field d30b5b4a-328d-47c3-a829-acbc0155b60c --><p>From birth onwards.</p><!-- end field d30b5b4a-328d-47c3-a829-acbc0155b60c --><!-- end item 995af068-65c3-4136-8ff8-8b919a0aec86 -->","topic":{"id":"4e83ca20-0eac-5432-adf1-cb9a0716c558","topicId":"41b219ac-b62a-42d3-9d76-7b3897b21bdd","topicName":"Angio-oedema and anaphylaxis","slug":"angio-oedema-anaphylaxis","lastRevised":"Last revised in November 2018","chapters":[{"id":"f7de7576-f193-57e1-8566-52f77c198d07","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"137d41e2-195c-5b6c-a42b-a2e7774ab4c5","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"2d19b26a-ca5e-5feb-8be8-12f596f24eed","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"76defb8d-d620-56bc-bf42-cc72dd02704f","slug":"changes","fullItemName":"Changes"},{"id":"0124664c-1848-504a-b629-b001f3d627e7","slug":"update","fullItemName":"Update"}]},{"id":"fd3fe5d3-198d-5e2e-afaa-1de509ee14b0","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"8c36d3c5-8fc2-58ba-91d9-2d00dbb17605","slug":"goals","fullItemName":"Goals"},{"id":"dbfbfeb0-8ad4-5a3d-8458-06af672eab12","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"bbc732dc-6fbc-5902-a5bf-890776f1df44","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"49ccfcd1-6054-5eac-b6a2-c85eb605ecfd","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"4c97855a-e489-54e6-8f4b-28dbc050951e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"71eafab9-7c66-5e57-aa08-197ad09eb9e7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2c158e9f-bfe1-56ea-a1fe-97e4da83b82d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ed1b7bb1-0232-5ceb-991c-c936ac2a3086","slug":"definition","fullItemName":"Definition"},{"id":"ac67665b-2b88-5df8-9a70-cc35f96825ae","slug":"causes-trigger-factors","fullItemName":"Causes/trigger factors"},{"id":"a4358430-db1f-55c2-9d68-6ce8076813ba","slug":"prevalence","fullItemName":"Prevalence"},{"id":"7ebee135-258e-58ce-a91e-947b8a2f9563","slug":"complications","fullItemName":"Complications"},{"id":"7c2a6ca1-0f6a-5a40-bc06-dbbbf95c57c1","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"4b20303c-5905-594a-a8c6-4f85e46cf3f9","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"005b06b8-18c4-569f-b1b3-3c6d1218ddf7","slug":"diagnosis-of-angio-oedema","fullItemName":"Diagnosis of angio-oedema"},{"id":"682e56cf-4c4d-5736-8db7-4cd4bfcab6e2","slug":"assessing-the-cause-of-angio-oedema","fullItemName":"Assessing the cause of angio-oedema"},{"id":"bf860a63-b9a4-5c14-bf1b-46423d3df7ad","slug":"diagnosis-of-anaphylaxis","fullItemName":"Diagnosis of anaphylaxis"},{"id":"fab5c932-e15e-5303-99e9-48f7d2e415b4","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"1c5f38ef-17d4-569d-ad54-b819fd953d6c","fullItemName":"Management","slug":"management","subChapters":[{"id":"654a5e70-49b7-58b4-b976-7e94c44b3074","slug":"angio-oedema-without-anaphylaxis","fullItemName":"Scenario: Angio-oedema without anaphylaxis"},{"id":"5759117d-4bde-53b6-b78d-7885ccbf431e","slug":"anaphylaxis-with-or-without-angio-oedema","fullItemName":"Scenario: Anaphylaxis with or without angio-oedema"}]},{"id":"6f94e28f-193d-587a-a11a-0a05a1be037f","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"b59ab8fd-de1f-555e-946a-c3a53b918da4","slug":"emergency-drug-doses","fullItemName":"Emergency drug doses"},{"id":"69e007b8-2046-5946-a7b5-de8f1bb9de9f","slug":"non-sedating-antihistamines-no-airway-involvement","fullItemName":"Non-sedating antihistamines (no airway involvement)"},{"id":"dac089ca-3b63-536d-9737-82806f78b88e","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"}]},{"id":"7ead2f48-36a4-5547-8570-4d4ab5898a73","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"a7653e34-460d-5737-b0c3-264ecc26dc68","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a713ee82-3188-50ea-a2bc-a562abd97621","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"7421fd02-2e34-5526-bd39-905aa772f800","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d24df800-eddc-5bf3-bea0-d556b5e01aed","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"af27ed5c-0853-5d16-91a4-5e5878ee9209","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"f7640a76-8bc4-569e-8b82-717e6bd5f041","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"b4778aa1-f37d-574f-8514-47ac86bf2c2e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"1c5f38ef-17d4-569d-ad54-b819fd953d6c","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"7f4e9c45-4df6-50a7-8b12-4110c3c3b571","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field 8d210667-6b4f-421f-9757-9e05f8aac76c --><h3>How should I manage a person with angio-oedema without any airway symptoms or signs of circulatory collapse?</h3><!-- end field 8d210667-6b4f-421f-9757-9e05f8aac76c -->","summary":null,"htmlStringContent":"<!-- begin item 9c01ffaf-7988-4eb1-8ec6-41927916b48f --><!-- begin field 70c4e15a-6752-4ec2-ae2c-fc3d049de691 --><p><strong>For people with rapidly developing angio-oedema </strong><strong><em>without </em>anaphylaxis:</strong></p><ul><li>Give slow intravenous (IV) or intramuscular (IM) chlorphenamine and hydrocortisone. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/prescribing-information/emergency-drug-doses/\">Recommended emergency drug doses</a> for more information.  </li><li>Arrange emergency admission.</li><li>Arrange a review after the person has been discharged from hospital.<ul><li><strong>If anaphylaxis developed during admission,</strong> see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/management/anaphylaxis-with-or-without-angio-oedema/#follow-up\">Follow up after hospital treatment for anaphylaxis</a> for more information.</li><li><strong>If anaphylaxis did not develop during admission, </strong>see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/management/angio-oedema-without-anaphylaxis/#follow-up\">Follow up after hospital treatment for angio-oedema</a> for more information.</li></ul></li></ul><p><strong>For people with stable angio-oedema </strong><strong><em>without </em>anaphylaxis:</strong></p><ul><li><strong>Try to identify the unde</strong><strong>rlying <a class=\"topic-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/diagnosis/assessing-the-cause-of-angio-oedema/\">cause</a></strong><strong> so that further episodes can be avoided. </strong><ul><li>For people taking an angiotensin-converting enzyme (ACE) inhibitor:<ul><li>Stop treatment immediately, and consider starting an alternative drug treatment.</li><li>If possible, avoid angiotensin-II receptor antagonists as these can also trigger episodes of angio-oedema.</li></ul></li></ul></li><li><strong>For people with mild symptoms of angio-oedema, </strong>treatment may not be needed.</li><li><strong>For people with symptoms requiring treatment:</strong><ul><li>Offer a non-sedating antihistamine (such as cetirizine, fexofenadine, or loratadine) for up to 6 weeks (use clinical judgement to determine the duration of treatment). <ul><li>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/prescribing-information/non-sedating-antihistamines-no-airway-involvement/\">Prescribing information</a> for detailed information on choice and licensed doses of non-sedating antihistamines.</li></ul></li><li>If symptoms are severe, give a short course of an <a class=\"topic-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/prescribing-information/oral-corticosteroids/\">oral corticosteroid</a> (for example prednisolone 40 mg daily for up to 7 days) in addition to the non-sedating oral antihistamine. </li><li>Advise the person to seek immediate medical help (by dialling 999 or attending A&E) if symptoms progress rapidly or if symptoms of <a class=\"topic-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/diagnosis/diagnosis-of-anaphylaxis/\">anaphylaxis</a> develop.</li></ul></li><li><strong>Review the person to assess response to treatment, </strong>using clinical judgement to determine the frequency and means of review (for example daily review, either face to face or by telephone). <ul><li><strong>If symptoms improve, </strong>consider the need for further antihistamine treatment, based on an assessment of the underlying cause, and the duration of symptoms before treatment. <ul><li><strong>If it is likely that symptoms will be persistent or recurrent,</strong> prescribe daily antihistamine treatment<strong> </strong>for 3–6 months, then review. </li><li><strong>If the person has a long history of urticaria and angio-oedema,</strong> prescribe daily antihistamine treatment for 6–12 months, with gradual withdrawal over a period of weeks.</li><li><strong>If symptoms were short-lived and frequent recurrence thought unlikely, </strong>prescribe treatment to be taken as required or prophylactically (for example prior to occasions when symptoms would be most unwelcome, such as business meetings). </li></ul></li><li><strong>If there is no improvement or symptoms worsen on treatment,</strong> consider admission to hospital. Worsening symptoms may be cutaneous (increased swelling) or development of other features (such as abdominal pain, vomiting, or rhinitis). </li></ul></li><li><strong>Refer the person to a dermatologist or immunologist if:</strong><ul><li><a class=\"topic-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/background-information/causes-trigger-factors/\">Hereditary or acquired angio-oedema</a> is suspected.</li><li>Symptoms persist or reoccur 3 months after stopping treatment with an ACE inhibitor.</li><li>The cause of angio-oedema is not identifiable or avoidable.</li></ul></li><li><strong>For people awaiting specialist review who are at risk of anaphylaxis, </strong>seek specialist advice about prescribing an adrenaline auto-injector device to be used in the event of anaphylaxis before their hospital appointment.<ul><li>People at risk of anaphylaxis include people with co-existing asthma, chronic obstructive pulmonary disease, or heart disease, people who have experienced angio-oedema with trace amounts of an allergen/trigger, and people who cannot easily avoid an allergen.</li><li>If an adrenaline auto-injector device is indicated in a person taking a beta-blocker, consider discontinuing the beta-blocker if possible, as it can interfere with the action of adrenaline.</li></ul></li><li><strong>Provide additional information on angio-oedema. </strong>For example:<ul><li>NHS A-Z has printable information on <a data-hyperlink-id=\"bb29c14d-6b52-47a4-b4f6-a99300bf8367\" href=\"http://www.nhs.uk/conditions/Nettle-rash/Pages/Introduction.aspx\">A</a><a data-hyperlink-id=\"b7cc6755-554c-48b2-8fcc-a99300bf83d6\" href=\"http://www.nhs.uk/conditions/Angioedema/Pages/Introduction.aspx\">ngioedema</a>.</li><li>The British Association of Dermatologists (BAD) has produced an information leaflet on <a data-hyperlink-id=\"45b1de3b-7327-4048-8e00-a99300bf843b\" href=\"http://www.bad.org.uk/shared/get-file.ashx?id=184&itemtype=document\">Urticaria and Angioedema</a>.</li><li>Allergy UK, a national charity dedicated to supporting allergy sufferers in the UK, has a factsheet on <a data-hyperlink-id=\"1ba4c62e-9a33-4147-ade5-a99300bf844d\" href=\"http://www.allergyuk.org/downloads/factsheets/types-of-allergy/urticaria-and-angiodema.pdf\">Urticaria and Angioedema</a>. It also has a dedicated <a data-hyperlink-id=\"63e06f8b-2f32-489d-beae-a99300bf8475\" href=\"http://www.allergyuk.org/getting-help/allergy-uk-helpline\">helpline</a> and an <a data-hyperlink-id=\"80cfb9f8-2cb0-434c-82bc-a99300bf84a7\" href=\"http://forum.allergyuk.org/\">online forum</a> for people who have allergies.</li></ul></li></ul><!-- end field 70c4e15a-6752-4ec2-ae2c-fc3d049de691 --><!-- end item 9c01ffaf-7988-4eb1-8ec6-41927916b48f -->","subChapters":[{"id":"8ce3e3a5-619d-50fc-bf4a-6c156c94fb07","slug":"basis-for-recommendation-0bf","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field b01ce300-6576-47d1-a72a-caf4b486d562 --><h4>Basis for recommendation</h4><!-- end field b01ce300-6576-47d1-a72a-caf4b486d562 -->","summary":null,"htmlStringContent":"<!-- begin item 0bf818d7-c0ca-4f90-a8f6-2f206a8011a6 --><!-- begin field 6059a335-fac6-4e27-b025-3265d8078a45 --><h5><strong>Managing people with rapidly developing angio-oedema without anaphylaxis</strong></h5><ul><li>CKS could not find any evidence, guidelines, or expert opinion relating to the management of a person with rapidly developing angio-oedema without other clinical features of anaphylaxis.</li><li>Expert opinion in a review article is that the rapid development of symptoms is associated with an increased risk of a severe anaphylactic reaction [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Stoloff, 2010</a>]. CKS therefore recommends intravenous or intramuscular chlorphenamine and hydrocortisone to treat rapidly developing angio-oedema because a rapid response to treatment will reduce the risk of an anaphylactic reaction developing.</li></ul><h5>Managing people with stable angio-oedema without anaphylaxis</h5><ul><li>These recommendations are largely based on the <em>BSACI guideline for the management of chronic urticaria and angioedema </em>published by the British Society for Allergy and Clinical Immunology (BSACI) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Powell, 2015</a>], the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">BNF 73, 2017</a>], and a review article on urticaria and angio-oedema [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">BMJ, 2016</a>].<ul><li>The management of angio-oedema generally depends on the cause, duration, and severity [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Powell, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">BMJ, 2016</a>]. For example:<ul><li>Angio-oedema with urticaria is usually mast cell- or histamine mediated and responds well to avoidance of triggers and treatment with oral antihistamines and corticosteroids [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Powell, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">BMJ, 2016</a>].</li><li>Drug-induced angio-oedema requires identification and cessation of the drug responsible. Antihistamines, corticosteroids, and adrenaline have traditionally been used to manage this condition, but their efficacy remains unproven [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Kaplan, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Powell, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">BMJ, 2016</a>]. </li><li>Hereditary and acquired angio-oedema are not histamine mediated and hence do not respond to treatment with antihistamines or corticosteroids [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Kaplan, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Cicardi, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">BMJ, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">ASCIA, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">BNF 73, 2017</a>].</li></ul></li><li>Although antihistamines are not specifically licensed for the treatment of angio-oedema (but for the treatment of chronic idiopathic urticaria), they are widely used for controlling symptoms in people with angio-oedema.</li><li>The recommendations to initially offer a non-sedating oral antihistamine for up to 6 weeks is based on what CKS considers to be good clinical practice, bearing in mind that the symptoms of acute angio-oedema last for less than 6 weeks [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Powell, 2015</a>]. CKS also recommends reviewing the person to assess response to treatment, as a rapid development of symptoms is associated with an increased risk of a severe anaphylactic reaction [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Stoloff, 2010</a>].</li></ul></li></ul><h5>Considering the need for further antihistamine treatment if symptoms improve</h5><ul><li>This recommendation is based on the <em>BSACI guideline for the management of chronic urticaria and angioedema</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Powell, 2015</a>], which states that once symptom control has been achieved, daily antihistamine treatment for 6–12 months is advised for people with a long history of urticaria and angio-oedema, and as required or prophylactic treatment for people with infrequent symptoms. </li><li>The BSACI guideline also recommends daily antihistamine treatment for 3–6 months for most people with chronic spontaneous urticaria. Since the pathological process of angio-oedema is similar to that of urticaria, CKS has extrapolated this recommendation to situations where it is likely that angio-oedema symptoms will be persistent or recurrent.</li></ul><h5>Managing treatment failure</h5><ul><li>For people who do not respond to standard doses, the BSACI guideline recommends incremental updosing of the first-line antihistamine treatment (up to fourfold higher than the standard licensed dose); however, CKS recommends considering hospital admission in this case as these people may be at increased risk of an anaphylactic reaction.</li></ul><h5>Referral</h5><ul><li>These recommendations are largely based on the <em>BSACI guideline for the management of chronic urticaria and angioedema</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Powell, 2015</a>], the BNF [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">BNF 73, 2017</a>], and on review articles on angio-oedema [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Kaplan, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Cicardi, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">BMJ, 2016</a>].<ul><li>Hereditary and acquired angio-oedema are not histamine mediated and hence do not respond to treatment with antihistamines or corticosteroids. Secondary care treatment options include plasma-derived C1 esterase inhibitor (C1-INH) concentrates, ecallantide (a kallikrein inhibitor [kallikrein is involved in the production of bradykinin]), icatibant (a bradykinin receptor antagonist), prophylactic doses of C1-INH, and long-term prophylaxis with danazol (an androgen) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Kaplan, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Cicardi, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">BMJ, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">ASCIA, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">BNF 73, 2017</a>].</li><li>Episodes of angiotensin-converting enzyme (ACE) inhibitor-related angio-oedema may persist for several months after stopping the drug [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Powell, 2015</a>]. CKS pragmatically recommends referring the person to an immunologist or dermatologist for consideration of other causes of angio-oedema if symptoms persist or reoccur 3 months after stopping treatment.</li><li>The recommendation to refer people with angio-oedema with an unidentifiable or unavoidable cause/trigger is based on what CKS considers to be good clinical practice, as investigations may be indicated to identify associated conditions or trigger factors, or to exclude differential diagnoses. </li></ul></li></ul><h5>Managing people awaiting specialist review who are at risk of severe anaphylaxis</h5><ul><li>The recommendation to seek specialist advice about providing an adrenaline injector for people who have experienced angio-oedema and are at increased risk of anaphylaxis is based on the <em>BSACI guideline: prescribing an adrenaline auto-injector</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Ewan, 2016</a>], which states that:<ul><li>An adrenaline auto-injector should be prescribed for people at risk of anaphylaxis.</li><li>Assessment of people who never suffered anaphylaxis but are considered to be at risk can be difficult and requires expertise.</li></ul></li><li>The list of people at risk of anaphylaxis is taken from the BSACI guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Ewan, 2016</a>] and a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Stoloff, 2010</a>].</li><li>The recommendation to consider discontinuing a beta-blocker (if possible) when adrenaline is prescribed is based on expert opinion in a review article on urticaria and angio-oedema [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">BMJ, 2016</a>]. In addition, expert opinion in the Resuscitation Council (UK) guideline <em>Emergency treatment of anaphylactic reactions: Guidelines for healthcare providers </em>is that the decision to prescribe a beta-blocker to a person at increased risk of an anaphylactic reaction should be made only after assessment by an allergist and cardiologist [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Resuscitation Council (UK), 2012</a>].</li></ul><h5>Providing additional information on angio-oedema</h5><ul><li>This recommendation is based on what CKS considers to be good clinical practice. In addition, the <em>BSACI guideline for the management of chronic urticaria and angioedema</em> states that in addition to elimination/avoidance of causes/triggers (where possible), symptomatic treatment, and a personalized management plan, the management of angio-oedema should include appropriate patient education [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Powell, 2015</a>].</li></ul><!-- end field 6059a335-fac6-4e27-b025-3265d8078a45 --><!-- end item 0bf818d7-c0ca-4f90-a8f6-2f206a8011a6 -->","subChapters":[]}]},{"id":"a49c8604-429e-51d8-a1c4-69ef18c81802","slug":"follow-up","fullItemName":"Follow up","depth":3,"htmlHeader":"<!-- begin field ee0c06ad-e03f-4965-90c9-24beee9b28a9 --><h3>How should I manage a person after hospital treatment for angio-oedema?</h3><!-- end field ee0c06ad-e03f-4965-90c9-24beee9b28a9 -->","summary":null,"htmlStringContent":"<!-- begin item 8864f254-f072-44ba-99af-d34825165499 --><!-- begin field e4d3d1bc-f163-4d29-8ec7-ac459763dc8b --><p><strong>Following hospital treatment for angio-oedema:</strong></p><ul><li><strong>Try to identify the underlying <a class=\"topic-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/background-information/causes-trigger-factors/\">cause/trigger</a> so that further episodes can be avoided.</strong><ul><li>For people taking an angiotensin-converting enzyme (ACE) inhibitor:<ul><li>Stop treatment immediately, and consider starting an alternative drug treatment.</li><li>If possible, avoid angiotensin-II receptor antagonists as these can also trigger episodes of angio-oedema.</li></ul></li></ul></li><li><strong>Ensure that treatment with a <a class=\"topic-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/prescribing-information/non-sedating-antihistamines-no-airway-involvement/#licensed-doses\">non-sedating antihistamine</a> (such as cetirizine, fexofenadine, or loratadine) has been offered.</strong> Based on an assessment of the underlying cause, and the duration of symptoms before treatment, treatment may be prescribed:<ul><li><strong>Daily for up to 6 weeks </strong>for people with acute allergic angio-oedema.</li><li><strong>Daily for 3–6 months</strong> if it is thought likely that symptoms will be persistent or recurrent, then reviewed.</li><li><strong>Daily for 6–12 months </strong>for people with a long history of urticaria and angio-oedema, with gradual withdrawal over a period of weeks.</li><li><strong>As required or prophylactically </strong>(for example prior to occasions when symptoms would be most unwelcome, such as business meetings) if symptoms were short lived and frequent recurrence thought unlikely. </li></ul></li><li><strong>Advise the person to seek immediate medical help (by dialling 999 or attending A&E)</strong> if symptoms progress rapidly or if symptoms of <a class=\"topic-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/diagnosis/diagnosis-of-anaphylaxis/\">anaphylaxis</a> develop.</li><li><strong>Ensure referral to a dermatologist or immunologist has been offered/arranged for people with:</strong><ul><li>Suspected <a class=\"topic-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/background-information/causes-trigger-factors/\">hereditary or acquired angio-oedema</a>.</li><li>Persistent or recurrent symptoms 3 months after stopping treatment with an ACE inhibitor.</li><li>Angio-oedema with an unidentifiable or unavoidable cause/trigger.</li></ul></li><li><strong>For people awaiting specialist review who are at risk of anaphylaxis, </strong>seek specialist advice about prescribing an adrenaline auto-injector device to be used in the event of anaphylaxis before their hospital appointment.<ul><li>People at risk of anaphylaxis include people with co-existing asthma, chronic obstructive pulmonary disease, or heart disease, people who have experienced angio-oedema with trace amounts of an allergen/trigger, and people who cannot easily avoid an allergen.</li><li>If an adrenaline auto-injector device is indicated in a person taking a beta-blocker, consider discontinuing the beta-blocker if possible, as it can interfere with the action of adrenaline.</li></ul></li><li><strong>Provide additional information on angio-oedema. </strong>For example:<ul><li>NHS A-Z has printable information on <a data-hyperlink-id=\"d2b1d764-e750-48ee-a926-a99200d46885\" href=\"http://www.nhs.uk/conditions/Nettle-rash/Pages/Introduction.aspx\">A</a><a data-hyperlink-id=\"4e34a80d-015e-40b6-bea5-a99200d468cd\" href=\"http://www.nhs.uk/conditions/Angioedema/Pages/Introduction.aspx\">ngioedema</a>.</li><li>The British Association of Dermatologists (BAD) has produced an information leaflet on <a data-hyperlink-id=\"2f623024-77bc-490a-9a60-a99200d4690a\" href=\"http://www.bad.org.uk/shared/get-file.ashx?id=184&itemtype=document\">Urticaria and Angioedema</a>.</li><li>Allergy UK, a national charity dedicated to supporting allergy sufferers in the UK, has a factsheet on <a data-hyperlink-id=\"a6b6343b-1551-47eb-9696-a99200d4691c\" href=\"http://www.allergyuk.org/downloads/factsheets/types-of-allergy/urticaria-and-angiodema.pdf\">Urticaria and Angioedema</a>. It also has a dedicated <a data-hyperlink-id=\"8e63dad3-8816-4f1b-969e-a99200d46939\" href=\"http://www.allergyuk.org/getting-help/allergy-uk-helpline\">helpline</a> and an <a data-hyperlink-id=\"4333378e-1f67-4ba8-b531-a99200d4696a\" href=\"http://forum.allergyuk.org/\">online forum</a> for people who have allergies.</li></ul></li></ul><!-- end field e4d3d1bc-f163-4d29-8ec7-ac459763dc8b --><!-- end item 8864f254-f072-44ba-99af-d34825165499 -->","subChapters":[{"id":"972242c8-e71c-5ceb-8a4e-788dabbe521a","slug":"basis-for-recommendation-466","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 441e3472-4999-4659-aec8-b14a3c71a4d7 --><h4>Basis for recommendation</h4><!-- end field 441e3472-4999-4659-aec8-b14a3c71a4d7 -->","summary":null,"htmlStringContent":"<!-- begin item 466f2385-44bf-4ce4-ae9b-bce7aabbe30e --><!-- begin field 757303c5-b2e6-4c6c-a734-db33bc196f3b --><h5>General management</h5><ul><li>These recommendations are largely based on the <em>BSACI guideline for the management of chronic urticaria and angioedema </em>published by the British Society for Allergy and Clinical Immunology (BSACI) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Powell, 2015</a>], the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">BNF 73, 2017</a>], and a review article on urticaria and angio-oedema [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">BMJ, 2016</a>].<ul><li>The management of angio-oedema generally depends on the cause, duration, and severity [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Powell, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">BMJ, 2016</a>]. For example:<ul><li>Angio-oedema with urticaria is usually mast cell- or histamine mediated and responds well to avoidance of triggers and treatment with oral antihistamines and corticosteroids [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Powell, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">BMJ, 2016</a>].</li><li>Drug-induced angio-oedema requires identification and cessation of the drug responsible. Antihistamines, corticosteroids, and adrenaline have traditionally been used to manage this condition, but their efficacy remains unproven [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Kaplan, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Powell, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">BMJ, 2016</a>]. </li><li>Hereditary and acquired angio-oedema are not histamine mediated and hence do not respond to treatment with antihistamines or corticosteroids [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Kaplan, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Cicardi, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">BMJ, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">ASCIA, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">BNF 73, 2017</a>].</li></ul></li><li>Although antihistamines are not specifically licensed for the treatment of angio-oedema (but for the treatment of chronic idiopathic urticaria), they are widely used for controlling symptoms in people with angio-oedema.</li></ul></li></ul><h5>Duration of antihistamine treatment</h5><ul><li>Symptoms of acute angio-oedema last for less than 6 weeks [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Powell, 2015</a>], so antihistamine treatment may be required for up to 6 weeks for people with acute allergic angio-oedema.</li><li>The <em>BSACI guideline for the management of chronic urticaria and angioedema</em> states that once symptom control has been achieved, daily antihistamine treatment for 6–12 months is advised for people with a long history of urticaria and angio-oedema, and as required or prophylactic treatment for people with infrequent symptoms [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Powell, 2015</a>]. </li><li>The BSACI guideline also recommends daily antihistamine treatment for 3–6 months for most people with chronic spontaneous urticaria. Since the pathological process of angio-oedema is similar to that of urticaria, CKS has extrapolated this recommendation to situations where it is likely that angio-oedema symptoms will be persistent or recurrent.</li></ul><h5>Referral</h5><ul><li>These recommendations are largely based on the <em>BSACI guideline for the management of chronic urticaria and angioedema</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Powell, 2015</a>], the BNF [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">BNF 73, 2017</a>], and on review articles on angio-oedema [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Kaplan, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Cicardi, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">BMJ, 2016</a>].<ul><li>Hereditary and acquired angio-oedema are not histamine mediated and hence do not respond to treatment with antihistamines or corticosteroids. Secondary care treatment options include plasma-derived C1 esterase inhibitor (C1-INH) concentrates, ecallantide (a kallikrein inhibitor; kallikrein is involved in the production of bradykinin), icatibant (a bradykinin receptor antagonist), prophylactic doses of C1-INH, and long-term prophylaxis with danazol (an androgen) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Kaplan, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Cicardi, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">BMJ, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">ASCIA, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">BNF 73, 2017</a>].</li><li>Episodes of angiotensin-converting enzyme (ACE) inhibitor-related angio-oedema may persist for several months after stopping the drug [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Powell, 2015</a>]. CKS pragmatically recommends referring the person to an immunologist for consideration of other causes of angio-oedema if symptoms persist or reoccur 3 months after stopping treatment.</li><li>The recommendation to refer people with angio-oedema with an unidentifiable or unavoidable cause/trigger is based on what CKS considers to be good clinical practice, as investigations may be indicated to identify associated conditions or trigger factors, or to exclude differential diagnoses. </li></ul></li></ul><h5>Managing people awaiting specialist review who are at risk of severe anaphylaxis</h5><ul><li>The recommendation to seek specialist advice about providing an adrenaline injector for people who have experienced angio-oedema and are at increased risk of anaphylaxis is based on the <em>BSACI guideline: prescribing an adrenaline auto-injector</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Ewan, 2016</a>], which states that:<ul><li>An adrenaline auto-injector should be prescribed for people at risk of anaphylaxis.</li><li>Assessment of people who never suffered anaphylaxis but are considered to be at risk can be difficult and requires expertise.</li></ul></li><li>The list of people at risk of anaphylaxis is taken from the BSACI guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Ewan, 2016</a>] and a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Stoloff, 2010</a>].</li><li>The recommendation to consider discontinuing a beta-blocker (if possible) when adrenaline is prescribed is based on expert opinion in a review article on urticaria and angio-oedema [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">BMJ, 2016</a>]. In addition, expert opinion in the Resuscitation Council (UK) guideline <em>Emergency treatment of anaphylactic reactions: Guidelines for healthcare providers </em>is that the decision to prescribe a beta-blocker to a person at increased risk of an anaphylactic reaction should be made only after assessment by an allergist and cardiologist [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Resuscitation Council (UK), 2012</a>].</li></ul><h5>Providing additional information on angio-oedema</h5><ul><li>This recommendation is based on what CKS considers to be good clinical practice. In addition, the <em>BSACI guideline for the management of chronic urticaria and angioedema</em> states that in addition to elimination/avoidance of causes/triggers (where possible), symptomatic treatment, and a personalized management plan, the management of angio-oedema should include appropriate patient education [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angio-oedema-anaphylaxis/references/\">Powell, 2015</a>].</li></ul><!-- end field 757303c5-b2e6-4c6c-a734-db33bc196f3b --><!-- end item 466f2385-44bf-4ce4-ae9b-bce7aabbe30e -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}